Technologies in use and on the horizon could change aseptic processing in ways that seemed inconceivable years ago but approaches to aseptic process validation still need to move beyond their 1970s roots.
James E. Akers
Advertisement
James E. Akers is the president of Akers Kennedy & Associates, PO Box 22562, Kansas City, MO 64113, akainckc@aol.com.
Articles by James E. Akers
Isolators offer a safety and economic advantage for next-generation regenerative medicine products.
Advertisement
Latest Updated Articles
Aseptic Processing for Cytotherapy, Regenerative Medicine, and Tissue-Engineered ProductsPublished: October 2nd 2015 | Updated:
Aseptic Processing Practices: Reviewing Three Decades of ChangePublished: August 1st 2020 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
2
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
3
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
4
